Get the latest tech news
Scientists Will Test a Cancer-Hunting mRNA Treatment
Strand Therapeutics has figured out a way to turn the molecule on and off in certain tissues to more precisely treat tumors.
Today, the biotech company announced that the US Food and Drug Administration has greenlit a clinical trial testing the approach in cancer patients with solid tumors. Philip Santangelo, an mRNA researcher at the Winship Cancer Institute of Emory University, says there are benefits to Strand’s programmable approach even with injecting it at the site of a tumor. But like computer circuits, genetic ones can occasionally make mistakes, says Ron Weiss, a professor of biological engineering at MIT who cofounded Strand and now acts as an adviser.
Or read this on Wired
